25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

Abstract

The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN), is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small cell lung cancer (NSCLC). We aimed to assess if baseline LIPI correlates with durvalumab efficacy after chemoradiotherapy (ChRT) in the locally advanced setting.